AR105560A1 - Constructos de anticuerpo para msln y cd3 - Google Patents

Constructos de anticuerpo para msln y cd3

Info

Publication number
AR105560A1
AR105560A1 ARP160102339A ARP160102339A AR105560A1 AR 105560 A1 AR105560 A1 AR 105560A1 AR P160102339 A ARP160102339 A AR P160102339A AR P160102339 A ARP160102339 A AR P160102339A AR 105560 A1 AR105560 A1 AR 105560A1
Authority
AR
Argentina
Prior art keywords
antibody construct
msln
polynucleotide
antibody constructs
binds
Prior art date
Application number
ARP160102339A
Other languages
English (en)
Spanish (es)
Inventor
Bailis Julie
Nahrwold Elisabeth
Hoffmann Patrick
Rau Doris
Bluemel Claudia
Anlahr Jonas
Kufer Peter
Raum Tobias
Original Assignee
Amgen Res Munich Gmbh
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh, Amgen Inc filed Critical Amgen Res Munich Gmbh
Publication of AR105560A1 publication Critical patent/AR105560A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ARP160102339A 2015-07-31 2016-08-01 Constructos de anticuerpo para msln y cd3 AR105560A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562199939P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
AR105560A1 true AR105560A1 (es) 2017-10-18

Family

ID=60245272

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102339A AR105560A1 (es) 2015-07-31 2016-08-01 Constructos de anticuerpo para msln y cd3

Country Status (2)

Country Link
AR (1) AR105560A1 (fr)
MA (1) MA42535B1 (fr)

Also Published As

Publication number Publication date
MA42535A (fr) 2018-06-06
MA42535B1 (fr) 2024-01-31

Similar Documents

Publication Publication Date Title
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CL2020003416A1 (es) Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268)
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
MX2021009793A (es) Constructos de anticuerpo para dll3 y cd3.
MX2017001402A (es) Constructos de anticuerpos para cdh19 y cd3.
UY35286A (es) Construcciones de anticuerpos para CDH19 y CD3
CL2017002641A1 (es) Construcciones de anticuerpos biespecíficos contra cdh3 y cd3
AR105560A1 (es) Constructos de anticuerpo para msln y cd3
AR133026A2 (es) Constructos de anticuerpo para dll3 y cd3
AR105559A1 (es) Constructos de anticuerpo para cd70 y cd3
AR105558A1 (es) Constructos de anticuerpo para dll3 y cd3
AR105562A1 (es) Constructos de anticuerpo para receptor del factor de crecimiento epidérmico variante viii (egfrviii) y el antígeno cd3
AR105561A1 (es) Constructos de anticuerpo para el receptor de la tirosina quinasa (flt3) y el antígeno cd3
UY40424A (es) Constructos biespecíficos para dll3 y cd3
AR094598A1 (es) Construcciones de anticuerpos para cdh19 y cd3